Skip to main content

Sangamo Therapeutics(SGMO-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference

Business Wire - Tue Jan 4, 2022

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIOCONNECT Virtual Conference on Monday, January 10th at 7:00 a.m. Eastern Time.

The virtual session may be accessed on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will also be available on the Sangamo Therapeutics website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. For more information about Sangamo, visit www.sangamo.com.

Provided Content: Content provided by Business Wire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

inside the market
Short sales on the TSX: What bearish investors are betting against
Larry MacDonald